The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances ...

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections ...

Although cures for age-related macular degeneration are elusive, the case for prevention through nutrition looks strong and ...

Purpose To evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions. Methods Retrospective multicenter analysis of intravitreal ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or ‘wet’ age-related macular ...